{
  "ticker": "ZVRA",
  "company_name": "Zevra Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03460652",
      "title": "KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "ADHD",
      "start_date": "2018-03-13",
      "completion_date": "2019-07-09",
      "enrollment": 0,
      "sponsor": "Zevra Therapeutics"
    },
    {
      "nct_id": "NCT06773026",
      "title": "Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Medium-chain Acyl-CoA Dehydrogenase Deficiency",
      "start_date": "2025-06-30",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Jerry Vockley, MD, PhD"
    },
    {
      "nct_id": "NCT03292952",
      "title": "KP415 Classroom Study in Children (6-12 Years of Age) With ADHD",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "ADHD",
      "start_date": "2017-12-20",
      "completion_date": "2018-05-16",
      "enrollment": 0,
      "sponsor": "Zevra Therapeutics"
    },
    {
      "nct_id": "NCT07125066",
      "title": "An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE1",
      "condition": "Combined D,L-2-hydroxyglutaric Aciduria",
      "start_date": "2025-07-30",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Jerry Vockley, MD, PhD"
    },
    {
      "nct_id": "NCT05668754",
      "title": "Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Idiopathic Hypersomnia",
      "start_date": "2022-12-28",
      "completion_date": "2024-03-21",
      "enrollment": 0,
      "sponsor": "Zevra Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE3": 2,
      "PHASE2": 2,
      "PHASE1": 1
    },
    "by_status": {
      "COMPLETED": 3,
      "RECRUITING": 1,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 2,
    "completed_trials": 3,
    "conditions": [
      "ADHD",
      "Combined D,L-2-hydroxyglutaric Aciduria",
      "Idiopathic Hypersomnia",
      "Medium-chain Acyl-CoA Dehydrogenase Deficiency"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:23:06.212983",
    "search_query": "Zevra Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Zevra+Therapeutics,+Inc."
  }
}